GeneDx Holdings Corp expected to post a loss of $1.31 a share - Earnings Preview

GeneDx Holdings

28/10/2023 03:02

* GeneDx Holdings Corp  WGS.OQ   WGS.O  is expected to show
a fall
in quarterly revenue when it reports  results 
    * The Stamford Connecticut-based  company is expected to
report  a
37.0% decrease in revenue to $52.406 million from $83.23 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for GeneDx Holdings
Corp is
for a loss of $1.31 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GeneDx
Holdings
Corp is $9.25​, above​ its last closing price of $2.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.41       -1.31      -1.64     Missed  -24.9
 Mar. 31 2023  -1.36       -2.14      -2.44     Missed  -14.2
 Dec. 31 2022  -4.84       -5.28      -8.25     Missed  -56.2​
 Sep. 30 2022  -6.91       -7.01      -6.60     Beat    5.9
 ​​Jun.        -6.61       -6.93      -8.25     Missed  -19
 30 2022                                                
 Mar. 31 2022  -10.54      -10.19     -10.23    Missed  -0.4​
 Dec. 31 2021  -8.45       -8.50      -5.61     Beat    34
 Sep. 30 2021  -6.23       -6.20      -14.19    Missed  -128.7
 This summary was machine generated October 28 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated